Clinical Trial Update: Recurrence of Bladder Cancer After Transurethral Resection With Hexvix [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating recurrence of bladder cancer after transurethral resection with Hexvix has been withdrawn; no further recruitment or results are expe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Hexvix (hexaminolevulinate hydrochloride)

Snippet

Sponsor: GE Healthcare | Conditions: Bladder Cancer | Phase 4 | Status: WITHDRAWN